Research programme: peptide-drug conjugates - Phi Pharma

Drug Profile

Research programme: peptide-drug conjugates - Phi Pharma

Latest Information Update: 23 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Phi Pharma
  • Developer Drugs for Neglected Diseases Initiative Foundation; HES-SO Valais-Wallis; Phi Pharma
  • Class Drug conjugates; Peptides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Acute myeloid leukaemia; Leishmaniasis

Highest Development Phases

  • Preclinical Acute myeloid leukaemia
  • Research Leishmaniasis

Most Recent Events

  • 26 Apr 2017 Research programme: peptide-drug conjugates - Phi Pharma is available for licensing as of 26 Apr 2017. http://www.phi-pharma.com (Phi Pharma website, April 2017)
  • 26 Apr 2017 Phi Pharma has patent protection for peptide technology (Phi Pharma website, April 2017)
  • 12 Oct 2016 Phi Pharma and HES-SO Valais-Wallis agree to co-develop peptide-drug conjugates for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top